Our Business

With the rapidly growing global metabolic disease epidemic, which includes diabetes and obesity, there is a significant need to bring safer, more effective medications to physicians and patients world-wide. InteKrin’s business strategy, under the guidance of InteKrin’s experienced Management Team and world-class Scientific Advisory Board and Board of Directors , is to build a robust portfolio of high-potential products through in-licensing clinical-stage therapeutic candidates to meet the growing patient needs. The InteKrin team uses its capabilities to rapidly and effectively shepherd these therapeutic candidates through critical development stages to de-risk them and maximize their commercial potential.  
Read More

Recent News

January 11, 2010

InteKrin Therapeutics Inc. will present at the 28th Annual JP Morgan Global Healthcare Conference at 4:00 p.m. Pacific Time on Monday, January 11, 2010, to be held at the Westin St. Francis in San Francisco, California.
Read More

September 30, 2009

InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
—Superior Side Effect Profile with Comparable Efficacy Relative to Actos® Demonstrated—

Read More